Nkarta, Inc. Files 8-K Report

Ticker: NKTX · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1787400

Nkarta, INC. 8-K Filing Summary
FieldDetail
CompanyNkarta, INC. (NKTX)
Form Type8-K
Filed DateMar 25, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

Related Tickers: NKTX

TL;DR

Nkarta filed an 8-K, standard procedure, check exhibits for details.

AI Summary

On March 25, 2024, Nkarta, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure and other events. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates Nkarta, Inc. is meeting its reporting obligations with the SEC, which is standard for publicly traded companies. It suggests ongoing corporate activity and transparency.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report, not indicating any immediate negative or positive material events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Nkarta, Inc.?

The filing serves as a Current Report for Nkarta, Inc. and includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was this 8-K filing submitted?

The filing was submitted on March 25, 2024.

What is Nkarta, Inc.'s principal executive office address?

Nkarta, Inc.'s principal executive offices are located at 1150 Veterans Boulevard, South San Francisco, CA 94080.

What is Nkarta, Inc.'s telephone number?

Nkarta, Inc.'s telephone number, including area code, is (925) 407-1049.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 984 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-03-25 06:05:51

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains statements regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would," and "future" or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include, but are not limited to, the Company's expected cash runway; the Company's position, plans, strategies, and timelines for the continued and future clinical development and commercial potential of NKX019; the therapeutic potential, accessibility, tolerability, and safety profile of NK cell therapies, including NKX019 for the treatment of autoimmune diseases, such as lupus nephritis; and plans and timelines for the future availability and presentation of NKX019 clinical data.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate Presentation, dated March 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nkarta, Inc. Date: March 25, 2024 By: /s/ Alicia Hager Alicia J. Hager, J.D., Ph.D. Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing